background
wu
ki
polyomavirus
pyv
discov
respiratori
tract
sampl
adult
children
polyomavirus
bkpyv
jcpyv
associ
ill
immunocompromis
patient
studi
suggest
higher
preval
wupyv
kipyv
popul
object
determin
whether
higher
preval
viral
load
wupyv
kipyv
exist
immunocompromis
children
compar
immunocompet
children
studi
design
measur
preval
viral
load
wu
ki
pyv
quantit
realtim
pcr
viral
dna
respiratori
tract
specimen
pediatr
hematologyoncolog
patient
immunocompet
control
acut
respiratori
ill
result
preval
wupyv
immunocompromis
popul
versu
control
popul
p
versu
respect
kipyv
p
mean
viral
load
copi
per
cell
ml
sampl
kipyv
higher
immunocompromis
group
compar
control
group
p
statist
differ
wupyv
higher
preval
seen
hematopoiet
stem
cell
transplant
recipi
compar
immunocompromis
patient
versu
p
viral
persist
demonstr
sequenti
sampl
kipyv
persist
seen
wupyv
conclus
higher
preval
wupyv
kipyv
immunocompromis
popul
compar
immunocompet
group
demonstr
higher
viral
load
kipyv
immunocompromis
group
may
suggest
increas
pathogen
potenti
popul
publish
elsevi
bv
polyomavirus
pyv
dna
virus
widespread
human
anim
includ
bkpyv
jcpyv
associ
diseas
mainli
immunocompromis
individu
kipyv
wupyv
human
polyomavirus
first
detect
nasal
wash
specimen
children
respiratori
tract
ill
pcr
report
preval
rang
wupyv
kipyv
determin
pcr
respiratori
specimen
patient
respiratori
tract
infect
compar
preval
wupyv
kipyv
virus
respiratori
specimen
immunocompromis
children
immunocompet
patient
institut
hypothes
virus
may
preval
immunocompromis
individu
consequ
reactiv
increas
suscept
primari
infect
viral
copi
per
cell
ml
sampl
measur
attempt
correl
viral
load
sever
infect
retrospect
cohort
studi
perform
use
respiratori
specimen
nasal
wash
tracheal
aspir
bronchoalveolar
lavag
inpati
outpati
children
hospi
tal
aurora
co
collect
januari
decemb
approv
obtain
colorado
multipl
institut
review
board
major
patient
acut
respiratori
ill
immunocompromis
group
consist
patient
seen
hematolog
oncolog
servic
includ
children
diagnos
hematolog
solid
organ
malign
bone
marrow
transplant
recipi
individu
chemotherapi
primari
immunodefici
control
inpati
outpati
children
hospit
patient
exclud
control
group
hiv
posit
solid
organ
transplant
recipi
diagnos
primari
immunodefici
receiv
immunosuppress
therapi
major
patient
acut
respiratori
ill
sever
immunocompromis
group
asymptomat
given
possibl
yearround
viral
reactiv
may
occur
immunocompromis
group
may
reflect
true
season
virus
timematch
control
select
agematch
control
order
match
season
match
control
case
calcul
provid
confid
interv
power
detect
differ
preval
previous
report
wupyv
viral
nucleic
acid
extract
respiratori
specimen
use
qiagen
viral
kit
qiagen
hilden
germani
follow
manufactur
instruct
dna
primer
probe
region
wupyv
genbank
access
number
kipyv
genbank
access
number
design
use
primer
express
softwar
appli
biosystem
foster
citi
ca
basic
local
align
search
tool
blast
search
primer
probe
sequenc
determin
sequenc
specif
wupyv
kipyv
control
pcr
polyomaviru
sequenc
jc
bk
lymphotroph
polyomaviru
lpv
merkel
cell
viru
mcv
confirm
analysi
primer
probe
set
wu
ki
pyv
follow
quantit
real
time
pcr
perform
abi
prism
sequenc
detector
real
time
assay
use
common
pcr
mix
cycl
condit
l
taqman
master
mix
appli
biosystem
foster
citi
ca
l
nm
primer
l
nm
correspond
probe
ng
sampl
nucleic
acid
extract
final
reaction
volum
l
cycl
follow
paramet
incub
min
c
follow
min
c
cycl
denatur
c
extens
c
min
result
express
cycl
threshold
c
plasmid
dna
standard
viral
target
includ
pcr
assay
concentr
copi
per
l
reaction
verifi
assay
sensit
result
convert
copi
number
plot
c
valu
standard
curv
use
serial
dilut
control
plasmid
known
concentr
viral
copi
number
express
copi
per
ml
sampl
copi
per
cell
viral
copi
number
normal
human
cell
specimen
use
creactiv
protein
crp
gene
copi
number
number
cell
present
sampl
calcul
valu
crp
copi
per
ng
dna
determin
use
standard
curv
method
describ
viral
copi
number
per
cell
obtain
divid
viral
copi
number
per
l
number
cell
per
l
viral
copi
number
per
volum
correct
sampl
volum
requir
extract
ng
nucleic
acid
assay
test
use
nasopharyng
specimen
found
contain
influenza
viru
influenza
b
viru
respiratori
syncyti
viru
rsv
parainfluenza
adenoviru
human
metapneumoviru
hmpv
control
addit
assay
test
use
human
genom
dna
well
wupyv
kipyv
plasmid
crossamplif
detect
specimen
indic
pcr
assay
high
specif
primer
probe
assay
characterist
crp
describ
elsewher
major
specimen
test
presenc
respiratori
virus
use
id
tag
respiratori
viral
panel
luminex
molecular
diagnost
toronto
canada
follow
virus
rsv
b
influenza
b
parainfluenza
hmpv
adenoviru
coronavirus
enterovirusrhinoviru
specimen
test
posit
wupyv
kipyv
previous
test
direct
fluoresc
antibodi
dfa
viral
cultur
subsequ
test
entir
respiratori
viral
panel
panel
result
quantifi
copi
number
given
present
posit
present
neg
reaction
effici
wupyv
kipyv
assay
determin
standard
curv
slope
effici
r
effici
r
kipyv
wupyv
respect
valu
indic
high
amplif
effici
quantit
realtim
pcr
assay
assay
linear
dynam
rang
order
magnitud
result
obtain
three
independ
experi
indic
lower
detect
limit
l
total
respiratori
specimen
test
respiratori
sampl
individu
hematologyoncolog
patient
immunocompromis
group
sampl
individu
control
group
result
report
copi
per
cell
copi
per
ml
method
normal
highli
correl
r
fig
demograph
immunocompromis
hematologyoncolog
control
group
describ
tabl
demograph
individu
test
posit
either
wupyv
kipyv
list
tabl
preval
wupyv
immunocompromis
group
compar
control
group
respect
p
preval
kipyv
respect
p
significantli
differ
clinic
pre
sentat
demograph
viral
load
coinfect
patient
test
posit
wupyv
kipyv
viru
list
tabl
viral
load
wupyv
kipyv
measur
group
higher
kipyv
viral
load
immunocompromis
group
geometr
mean
copiescel
copiesml
compar
control
group
geometr
mean
copiescel
copiesml
p
statist
signific
differ
viral
load
wupyv
group
addit
statist
signific
differ
observ
outpati
inpati
either
group
p
kipyv
p
wupyv
fig
detect
rate
coincid
respiratori
virus
statist
differ
among
group
wupyv
kipyv
respect
immunocompromis
group
respect
control
group
respiratori
virus
codetect
wupyv
kipyv
includ
common
respiratori
pathogen
shown
fig
respect
immunocompromis
group
patient
hematopoiet
stem
cell
transplant
hsct
recipi
posit
kipyv
compar
individu
immunocompromis
popul
p
patient
subgroup
posit
wupyv
patient
hematologyoncolog
group
sequenti
sampl
avail
test
subsequ
sampl
collect
two
week
apart
collect
three
four
week
apart
collect
month
apart
one
oncolog
patient
initi
present
respiratori
symptom
test
posit
kipyv
remain
posit
one
month
later
asymptomat
viral
load
decreas
copi
per
cell
time
period
four
subsequ
sampl
test
patient
nine
week
second
sampl
neg
kipyv
studi
show
preval
wupyv
kipyv
similar
hematologyoncolog
patient
compar
gener
pediatr
popul
howev
found
higher
viral
load
kipyv
immunocompromis
group
suggest
may
replic
viru
popul
similar
associ
observ
wupyv
group
infect
either
viru
occur
older
children
compar
control
may
indic
viralreactiv
median
mean
age
hematologyoncolog
group
higher
control
group
addit
higher
preval
kipyv
hematopoet
stem
cell
transplant
patient
compar
immunocompromis
patient
differ
viral
load
inpati
outpati
group
due
high
coinfect
rate
respiratori
virus
difficult
conclud
whether
viral
load
measur
correl
sever
ill
final
prolong
transmiss
either
viru
suggest
lack
viral
persist
two
studi
report
preval
virus
respiratori
tract
immunocompromis
patient
mourez
et
al
detect
higher
proport
kipyv
respiratori
tract
specimen
hsct
recipi
compar
patient
versu
p
popul
also
higher
preval
ki
hsct
recipi
compar
immunocompromis
patient
approach
statist
signific
p
therefor
popul
may
signific
patholog
kipyv
infect
clinic
characterist
hsct
patient
test
posit
significantli
differ
group
requir
studi
larger
studi
number
anoth
studi
venter
et
al
report
respiratori
tract
specimen
test
patient
wupyv
kipyv
hiv
posit
result
statist
signific
hiv
statu
unknown
case
popul
includ
hiv
posit
patient
group
deserv
studi
question
whether
virus
pathogen
potenti
remain
unansw
due
part
high
codetect
rate
virus
lack
specif
clinic
correl
howev
studi
first
measur
viral
load
wupyv
kipyv
respiratori
secret
attempt
differenti
patholog
immunolog
distinct
patient
popul
viral
load
measur
copi
per
ml
well
copi
per
cell
order
account
high
degre
variabl
viral
load
among
respiratori
sampl
depend
sampl
collect
method
site
collect
lack
viral
detect
sequenti
specimen
may
reflect
nonstandard
collect
specimen
rather
lack
viral
persist
one
limit
studi
inclus
sampl
differ
site
respiratori
tract
like
contribut
variabl
viral
load
ensur
wider
spectrum
diseas
present
given
ill
patient
like
bronchoalveolar
lavag
tracheal
aspir
viral
load
measur
shown
help
tool
analyz
respiratori
virus
rsv
human
bocaviru
other
rhinoviru
higher
viral
load
kipyv
immunosuppress
group
suggest
increas
pathogen
potenti
popul
correl
level
immunosuppress
viral
load
would
import
focu
studi
difficult
pursu
studi
given
multipl
diseas
state
variabl
durat
immunosuppress
therapi
small
sampl
size
prevent
standard
degre
immunosuppress
sinc
monoinfect
either
wupyv
kipyv
uncommon
small
sampl
size
preclud
statist
analysi
correl
viral
load
sever
present
day
ill
explor
differ
clinic
characterist
studi
clinic
featur
viral
load
predictor
ill
sever
current
investig
larger
patient
cohort
addit
viral
load
measur
respiratori
tract
specimen
asymptomat
individu
would
help
address
clinic
util
viral
load
measur
virus
question
pathogen
potenti
high
codetect
rate
respiratori
virus
found
wupyv
kipyv
group
similar
previou
report
specif
associ
virus
observ
coincid
infect
would
interest
area
research
given
pattern
copathogen
emerg
sever
virus
greer
et
al
report
rhinoviru
detect
result
decreas
likelihood
detect
adenoviru
coronavirus
influenza
bocaviru
human
metapneumoviru
rsv
parainfluenza
kipyv
hypothes
trigger
interferonrel
gene
induc
antivir
state
associ
observ
studi
infect
enterovirusrhinoviru
frequent
pathogen
associ
infect
kipyv
wupyv
group
luminex
test
perform
specimen
statist
signific
find
could
determin
conclus
preval
kipyv
wupyv
respiratori
sampl
higher
immunocompromis
popul
compar
gener
pediatr
popul
acut
respiratori
ill
howev
higher
viral
load
kipyv
immunocompromis
group
may
suggest
increas
pathogen
potenti
popul
particular
hsct
patient
may
greater
risk
sever
kipyv
infect
immunocompromis
patient
final
detect
viru
older
children
immunocompromis
state
compar
control
may
indic
viral
reactiv
research
fund
depart
pediatr
section
infecti
diseas
univers
colorado
school
medicin
aurora
colorado
nih
grant
